Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

PHASE2TerminatedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 26, 2014

Primary Completion Date

September 14, 2018

Study Completion Date

September 14, 2018

Conditions
Epidermolysis Bullosa
Interventions
DRUG

SD-101 dermal cream (6%)

SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.

Trial Locations (7)

27516

Chapel Hill

60611

Chicago

63110

St Louis

78218

San Antonio

94304

Palo Alto

98105

Seattle

07601

Hackensack

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amicus Therapeutics

INDUSTRY

collaborator

Food and Drug Administration (FDA)

FED

lead

Scioderm, Inc.

INDUSTRY